Brief: Cerevel Therapeutics Q3 Net Income USD -96.361 Million
01/11/2023 10:30
Nov 01 (Reuters) - Cerevel Therapeutics Q3 operating expenses USD 111.307 million
Recent news on Cerevel Therapeutics Holdings
See all newsBrief: Abbvie Reaffirms FY Adj Diluted EPS Guidance Range $10.71-$10.91
Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 62 cents a share - Earnings Preview
Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands